Bone selective protective effect of a novel bone-seeking estrogen on trabecular bone in ovariectomized rats

Calcified Tissue International

Volumn 93, Issue 2, 2013, Pages 172-183

  Zhao, Qiang ^a   Liu, Xiaodong ^b   Zhang, Lianfang ^a   Shen, Xing ^a   Qi, Jin ^a   Wang, Jinshen ^a   Qian, Niandong ^a   Deng, Lianfu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Tongji University School of Medicine   (China)

Author keywords

Bone seeking estrogen; Estrogen; Postmenopausal osteoporosis; Side effects; Trabecular architecture

Indexed keywords

BONE SEEKING ESTROGEN; DIGLYCINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE TURNOVER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TISSUE LEVEL; FEMALE; HISTOLOGY; ISOTOPE LABELING; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOBLAST; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIOACTIVITY; TRABECULAR BONE; UTERINE CERVIX HYPERTROPHY; WEIGHT GAIN;

ANIMALS; BIOMECHANICAL PHENOMENA; BODY WEIGHT; BONE AND BONES; BONE DENSITY; ESTRADIOL; ESTROGENS; FEMALE; IMINO ACIDS; MICE; MICE, INBRED C57BL; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TISSUE DISTRIBUTION; X-RAY MICROTOMOGRAPHY;

EID: 84880918363     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-013-9739-1     Document Type: Article

References (35)

1. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761-1767
2. Pacifici R (1996) Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11:1043-1051
3. Inada M, Miyaura C (2010) Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis. Clin Calcium 20:1467-1472
4. Pacifici R (1998) Cytokines, estrogen, and postmenopausal osteoporosis - the second decade. Endocrinology 139:2659-2661
5. Novack DV (2007) Estrogen and bone: osteoclasts take center stage. Cell Metab 6:254-256
6. Hadjidakis DJ, Androulakis II (2006) Bone remodeling. Ann N Y Acad Sci 1092:385-396
7. Raisz LG (1993) Bone cell biology: new approaches and unanswered questions. J Bone Miner Res 8(Suppl 2):S457-S465
8. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137
9. Güerri-Fernández RC, Diez-Perez A (2012) Is there a future for selective estrogen-receptor modulators in osteoporosis? Ther Adv Musculoskelet Dis 4:55-59
10. Simon JA (2012) What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 15(Suppl 1):3-10
11. Beral V, Banks E, Reeves G (1999) Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 4:191-210
12. LaCroix AZ, Burke W (1997) Breast cancer and hormone replacement therapy. Lancet 350(9084):1042-1043
13. Lacey JV Jr, Mink PJ, Lubin JH (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334-341
14. Daly E, Vessey MP, Hawkins MM (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348(9033):977-980
15. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366:2257-2266
16. Mueck AO (2012) Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 15(Suppl 1):11-17
17. Takeyama M, Nogami K, Okuda M, Sakurai Y, Matsumoto T, Tanaka I, Yoshioka A, Shima M (2008) Selective factor VIII and V inactivation by iminodiacetate ion exchange resin through metal ion adsorption. Br J Haematol 142:962-970
18. Wang D, Miller SC, Kopecková P, Kopecek J (2005) Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev 57:1049-1076
19. Miller SC, Pan H, Wang D, Bowman BM, Kopecková P, Kopecek J (2008) Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats. Pharm Res 25:2889-2895
20. Bauss F, Esswein A, Reiff K, Sponer G, Müller-Beckmann B (1996) Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats. Calcif Tissue Int 59:168-173
21. Gallo D, Zannoni GF, Apollonio P, Martinelli E, Ferlini C, Passetti G, Riva A, Morazzoni P, Bombardelli E, Scambia G (2005) Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause 12:589-600
22. Mo Z, Jiao X, Su H, Zheng H, Weng L (1998) The estrogenic activities of 2-[3-estrone-N-ethyl-piperazine-methyl]tetracycline (XW630) - a new compound with anti-osteoporosis activity. Yao Xue Xue Bao 33:645-649
23. Neale JR, Richter NB, Merten KE, Taylor KG, Singh S, Waite LC, Emery NK, Smith NB, Cai J, Pierce WM Jr (2009) Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg Med Chem Lett 19:680-683
24. Iwaniec UT, Samnegård E, Cullen DM (2001) Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH. Bone 29:352-360
25. Mukherjee M, Das AS, Das D (2006) Effects of garlic oil on postmenopausal osteoporosis using ovariectomized rats: comparison with the effects of lovastatin and 17beta-estradiol. Phytother Res 20:21-27
26. Kim TH, Jung JW, Ha BG, Hong JM, Park EK, Kim HJ, Kim SY (2011) The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. J Nutr Biochem 22:8-15
27. Duvall CL, Robert Taylor W, Weiss D, Guldberg RE (2004) Quantitative microcomputed tomography analysis of collateral vessel development after ischemic injury. Am J Physiol Heart Circ Physiol 287:H302-H310
28. Yoon KH, Cho DC, Yu SH, Kim KT, Jeon Y, Sung JK (2012) The change of bone metabolism in ovariectomized rats: analyses of microCT scan and biochemical markers of bone turnover. J Korean Neurosurg Soc 51:323-327
29. Zhao Q, Shen X, Zhang W, Zhu G, Qi J, Deng L (2012) Mice with increased angiogenesis and osteogenesis due to conditional activation of HIF pathway in osteoblasts are protected from ovariectomy induced bone loss. Bone 50:763-770
30. Seeman E, Delmas PD (2006) Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
31. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487-494
32. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137
33. McCann RM, Colleary G, Geddis C (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384-393
34. Fox J, Miller MA, Newman MK (2006) Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79:262-272
35. Lin JC, Grampp S, Link T (1999) Fractal analysis of proximal femur radiographs: correlation with biomechanical properties and bone mineral density. Osteoporos Int 9:516-524